Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2008
10/16/2008WO2007117706A3 Solid oral dosage form containing an enhancer
10/16/2008WO2007115289A8 Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer
10/16/2008WO2007115278A3 3,6,11-tricyclolide
10/16/2008WO2007109230A3 Nutrient compositions for the treatment and prevention of inflammation and disorders associated therewith
10/16/2008WO2007109178A9 Indole derivatives as inhibitors of histone deacetylase
10/16/2008WO2007108010A8 Taste masked pharmaceutical composition for oral solid dosage form and process for preparing the same using magnesium aluminium silicate
10/16/2008WO2007106854A3 Hydroxy and alkoxy substituted 1h-imidazonaphthyridines and methods
10/16/2008WO2007105058A8 Pyrazole compounds
10/16/2008WO2007104011A3 Inhibition of microtubule protrusion in cancer cells
10/16/2008WO2007102872A3 Compositions and methods related to controlled gene expression using viral vectors
10/16/2008WO2007101007A3 Aryl sulfonyl heterocycles
10/16/2008WO2007100905A3 Acryloyloxyethylphosphorylcholine containing polymer conjugates and their preparation
10/16/2008WO2007100901A3 Epinephrine dosing regimens
10/16/2008WO2007098113A3 Ccr3 inhibition for ocular angiogenesis and macular degeneration
10/16/2008WO2007092646A3 Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
10/16/2008WO2007070892A3 Useful indole compounds
10/16/2008WO2007062186A3 Methods of using small molecule compounds for neuroprotection
10/16/2008WO2007002720A8 An impurity of anastrozole intermediate, and uses thereof
10/16/2008WO2006115987A8 Use of a clobetasol spray formulation to treat psoriasis
10/16/2008WO2006069329A3 Therapy inhalation involving antisense oligonucleotides for treating idiopathic pulmonary fibrosis
10/16/2008WO2006015259A3 Compounds and compositions as modulators of steroid hormone nuclear receptors
10/16/2008WO2005117550A3 Composition and method for the treatment of tauopathies
10/16/2008US20080255643 Compositions and methods relating to prevention of chemotherapy-induced alopecia
10/16/2008US20080255510 Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
10/16/2008US20080255508 Drug releasing coatings for medical devices
10/16/2008US20080255499 Using alpha ketoamino acid; tissue toxicity; urogenital disorders
10/16/2008US20080255365 Microparticulate form of a Tetrahydropyridine derivative
10/16/2008US20080255363 Novel Form of S-Omeprazole
10/16/2008US20080255350 Substituted aza-indoles as inhibitors of poly(adp-ribose) polymerase (parp)
10/16/2008US20080255258 Polymerizing monoethylenically unsaturated compounds, crosslinking with an initiator, a crosslinker an acrylic monomer and styrene; functionalizing the acrylic bead polymers with diamines or aminoalcohols producing an ion exchange membrane
10/16/2008US20080255250 Compounds and Compositions for Delivering Active Agents
10/16/2008US20080255246 Carotenoids as pretreatments for mammals at risk of an ischemic event; ischemic osteonecrosis, peritoneal ischemia, chronic ocular disease, macular degeneration, diabetic retinopathy
10/16/2008US20080255245 Diphenyl ethene compounds; autoimmune diseases; transplant rejection; rheumatic diseases; multiple sclerosis; antiallergens; skin disorders; chronic obstructive pulmonary disease; anticancer agents; antiischemic agents
10/16/2008US20080255244 CaM Kinase II Inhibitor Improves Retinoic Acid Therapy and Inhibits the Proliferation of Myeloid Leukemia Cells
10/16/2008US20080255243 Stat3 as a theranostic indicator
10/16/2008US20080255242 Hci polymorphs of 3-((2-(dimethylamino)methyl(cyclohex-1-yl)) phenol
10/16/2008US20080255240 Obesity; dietetics; hypotensive agents; antidiabetic agents; dyslipidemia; cardiovascular disorders; osteoarthritis; gall bladder disease; endometrosis; anticancer agents; vascular system disorders; apoptosis
10/16/2008US20080255239 Analgesics; muscular disorders; diarrhea
10/16/2008US20080255238 Composition containing a thiourea derivative for preventing or treating pruritic or irritant skin diseases
10/16/2008US20080255236 Methods and Composition Comprising 2-[(3-Chlorophenyl)Amino] Phenylacetic Acid for Alzheimer's Disease
10/16/2008US20080255235 Inhibitor of a Levodopa-metabolising enzyme, a buffer, a sugar, an acid; Parkinson's disease
10/16/2008US20080255234 Rumen protected lysine
10/16/2008US20080255232 Naphthyl Derivatives as Inhibitors of Beta-Amyloid Aggregation
10/16/2008US20080255231 Crystalline form of [3-[ alpha -(Dimethylamino)-ethyl]phenyl]-N-methylethylcarbamate hydrogentartrate
10/16/2008US20080255230 Pain therapy; muscular disorders; diarrhea
10/16/2008US20080255229 Reduced potential for phlebitis; treating arrhythmia
10/16/2008US20080255228 Topical applying to skin; acne; alopecia
10/16/2008US20080255227 7-[(1R,3R,6R,7R)-3-(1,1-difluoropentyl)-3-hydroxy-2-oxabicyclo[4.3.0]nonane-8-one-7-yl]heptanoic acid and a glyceride; improved stability
10/16/2008US20080255226 Stabilized anthocyanin compositions
10/16/2008US20080255225 Botanical Extract Composition
10/16/2008US20080255224 Administering a cannabinoid agonist
10/16/2008US20080255223 Treatment and Prevention of Benign Pigmented Moles (Naevi) Using Artemisinine and the Derivatives Thereof
10/16/2008US20080255222 Pharmaceutically active benzsulfonamide derivatives as inhibitors of protein junkinases
10/16/2008US20080255221 Novel hydroxamates as therapeutic agents
10/16/2008US20080255220 Therapeutic Substituted Gamma Lactams
10/16/2008US20080255219 Rumen protected essential amino acids
10/16/2008US20080255218 N-benzylamino cyclic thioureas; obesity and related disorders; (N-(3-{(4S)-1-[(1S)-2-(benzylamino)-1-methylethyl]-3-[2-(3-fluorophenyl)ethyl]-2-thioxoimidazolidin-4-yl}propyl)guanidine
10/16/2008US20080255217 Administering 6-fluoro-2',5'-dioxospiro[chroman-4,4'-imidazolidine]-2-carboxamide; percutaneous transluminal coronary angioplasty
10/16/2008US20080255216 Diaryltriazoles as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase-1
10/16/2008US20080255214 Novel hydroxamates as therapeutic agents
10/16/2008US20080255213 4R)-2-(benzo[d][1,3]dioxol-5-yl)-N-decylthiazolidine-4-carboxamide; prostate cancer, breast cancer, ovarian cancer, skin cancer
10/16/2008US20080255212 disorders of lipid and/or carbohydrate metabolism, metabolic disorders, central nervous system disorders; 3-{2-Chloro-4-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazole-5-ylmethoxy]-phenyl}-4H-[1,2,4]oxadiazole-5-one
10/16/2008US20080255211 cannabinoid receptors modulators; metabolic syndrome, obesity, hyperlipidemia, type II diabetes, atherosclerosis, substance addiction, liver cirrhosis, schizophrenia, sexual dysfunction, anxiety; 5-(5-(5-bromoselenophen-2-yl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazol-3-yl)-3-tert-butyl-1,2,4-oxadiazole
10/16/2008US20080255210 1-Benzyl-3-[3-(3,5-dimethyl-phenyl)-5,5-dimethyl-[1,2,4]oxadiazol-4-yl]-urea; nuclear receptor-based inducible gene expression system
10/16/2008US20080255209 Combination of a NSAID and a PDE-4 inhibitor
10/16/2008US20080255207 5-Thioxo-1,5-Dihydro-2H-Pyrrol-2-One Derivatives As Liver X Receptor Modulators
10/16/2008US20080255206 Rxr Agonists and Antagonists, Alone or in Combination with Ppar Ligands, in the Treatment of Metabolic and Cardiovascular Diseases
10/16/2008US20080255205 protein kinase receptors (like Tie-2 and Aurora) modulators; to treat cancer, inflammation and related disorders; to regulate active angiogenesis, cell-signal transduction; 5-(3-(1H-tetrazol-5-yl)pyridin-2-yloxy)-N-(3-chlorobenzyl)-2-fluorobenzamide
10/16/2008US20080255203 substituted oxadiazole and derivatives; novel allosteric modulators; nicotinic acetylcholine receptors modulators; central nervous system disorders; analgesics; 2,5-di(pyridin-3-yl)-1,3,4-oxadiazole
10/16/2008US20080255202 Phenylthioacetic Acid Derivatives and Use Thereof
10/16/2008US20080255201 Ppar active compounds
10/16/2008US20080255200 Benzimidazole enriched with deuterium; administering along with other active drugs
10/16/2008US20080255199 Using 2-(((4-x-3,5-dimethyl(or1-oxo)pyridin-2-yl)methylthio)5-methoxy-1H-benzimidazole where x is a leaving group; oxidation; using titanium complex catalyst and a base
10/16/2008US20080255198 Biaryloxymethylarenecarboxylic acids as glycogen synthase activator
10/16/2008US20080255197 Aminoalkylpyridines; treating HIV infections; antiinflammatory agents; rheumatic diseases; elevating progesator and stem cell count
10/16/2008US20080255195 Psyvhological disorders; cognition activators
10/16/2008US20080255194 1-(4-(3-(4-(6-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)propoxy)-3-methoxy-d3-phenyl)ethanone substituted with deuterium ions; antipsycholtic agent
10/16/2008US20080255193 Comprising NK3 receptor antagonist talnetant, povidone, erythritol and Sodium Lauryl Sulfate; erythritol used as soluble filler in preparation of stable drug; dosage tablet or capsule
10/16/2008US20080255192 Methods and Compositions for Selectin Inhibition
10/16/2008US20080255191 Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors
10/16/2008US20080255190 Bactericides for grampositive and gramnegative infections
10/16/2008US20080255189 using an thiourea compound or carbonyl thiourea compound; therapy for drug resistant infections
10/16/2008US20080255188 Muscarinic Receptor Antagonists
10/16/2008US20080255187 5-ht4 receptor agonist compounds
10/16/2008US20080255186 Pyrazolo[3,4-B]Pyridine Compound, and Its Use as a Pde4 Inhibitor
10/16/2008US20080255185 Small-molecule modulators of trp-p8 activity
10/16/2008US20080255184 N-[3-(4-amino-7-pyridin-3-ylthieno[3,2-c]pyridin-3-yl)phenyl]-N'-[2-fluoro-5-(trifluoromethyl)phenyl]urea; lymphoma, melanoma, small cell lung , non-small cell lung, breast, colon and pancreatic cancer
10/16/2008US20080255183 N-[(3,5-dimethylisoxazol-4-yl)carbonyl]-3-{5-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]thiophen-2-yl}-L-alanine; treatment of solid tumors
10/16/2008US20080255182 Certain chemical entities, compositions, and methods
10/16/2008US20080255181 Podocytopenia; N-(3-[2-chlorophenyl]-propyl)-R- alpha -methyl-3-methoxybenzylamine; modulate the calcium sensing receptor
10/16/2008US20080255180 4-Substituted Azaadamantane Derivatives and Methods of Use Thereof
10/16/2008US20080255179 Modulate neuronal nicotinic receptor activity; attention deficit disorder, Parkinson's, Tourette's, schizophrenia, cognitive deficits, dementia; acute pain, post-surgical pain, chronic pain, inflammatory pain; 2-[1-azatricyclo[3.3.1.13,7]dec-4-ylidene]-N-(4-methylphenyl)acetamide
10/16/2008US20080255178 Azaadamantane Ester and Carbamate Derivatives and Methods of Use Thereof
10/16/2008US20080255177 Rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid; mTOR inhibitor
10/16/2008US20080255176 1-methyl-3 beta -hydroxymethyl-6-methoxy-1,2,3,4,4a alpha ,5,10, 10a beta -octahydrobenzo[q]quinoline; decrease on the intraocular pressure; glaucoma and myopia; excellent tolerability, and a long duration of action
10/16/2008US20080255175 4-Ethyl-4-(1,4-dioxo-3-azahept-5-enoxy-),9-desamino-camptothecin where the 9-amino may be present as dimethylamino with an alkyl sulfo group on carbon #8; Camptothecin derivatives having greater biological activity/enhanced stability, topoisomerase I inhibitors; side effect reductions; antitumor agents
10/16/2008US20080255174 Hydroalcoholic Extract Of Erythrina Mulungu, Pharmaceutical Compositions And Processes For Producing These Substances
10/16/2008US20080255173 Novel Specific Caspase-10 Inhibitors
10/16/2008US20080255172 Pyrimidine derivatives
10/16/2008US20080255171 Combination of Nilotinib with Farnesyl Transferase Inhibitors
1 ... 3039 3040 3041 3042 3043 3044 3045 3046 3047 3048 3049 3050 3051 3052 3053 3054 3055 3056 3057 3058 3059 ... 7860